



Instructions for Canada PCT National Phase Entry

I. Client Information

Name: _____
Address: _____
Tel.: _____
Fax: _____
E-mail: _____
Ref. No.: _____

II. Application Particulars

International Application No.	International Filing Date

Title of Invention: _____

Canadian National Phase Entry required under:

PCT Chapter I

PCT Chapter II

Convention priority claim(s) is based on:

Country	Application Serial Number	Filing Date

additional Convention priority claim(s) is attached

III. Inventor Information

- Please use the inventor information currently on file with WIPO
- Inventor information is supplied below if:
 - (a) PCT application is not yet published
 - (b) The information currently on file is not up to date

Inventor #1 (if applicable):

Name: _____
Address: _____

Inventor #2 (if applicable):

Name: _____
Address: _____

Inventor #3(if applicable):

Name: _____
Address: _____

Inventor #4 (if applicable):

Name: _____
Address: _____

Inventor #5 (if applicable):

Name: _____
Address: _____

information on additional inventor(s) is attached

IV. Applicant Information

- Please use the Applicant information currently on file with WIPO
- Applicant information is supplied below if:
 - (a) PCT application is not yet published
 - (b) The information currently on file with WIPO is not up to date
- Applicant(s) is the inventor(s)

Applicant #1 (if applicable):

Name: _____

Address: _____

Applicant #2 (if applicable):

Name: _____

Address: _____

information on additional applicant(s) is attached

V. Request for Examination¹

Request examination at time of filing

Defer request for examination

¹Canada uses a deferred examination system. The applicant must file a request for examination and pay the government examination fee within 5 years of the international filing date of the PCT application. Please indicate whether we should request examination when we file the application, or defer such request for the time being.

VI. Entity Size²

Applicant(s) does not claim small entity status

Applicant(s) claims small entity status and acknowledges and accepts the risks of incorrectly claiming small entity status. Please forward a small entity declaration for signature by the Applicant(s).

²A “small entity” for fee purposes is an entity that employs 50 or fewer employees or that is a university. Small entity status does not apply to an entity that (a) is controlled directly or indirectly by an entity, other than a university, that employs more than 50 employees; or (b) has transferred or licensed or has an obligation, other than a contingent obligation, to transfer or license any right in the invention to an entity, other than a university, that employs more than 50 employees.

A Canadian patent can potentially be invalidated if any fee is improperly paid on the small entity scale. If there is any doubt as to entity status, we recommend against claiming small entity status.

VII. Accompanying Documents

PCT Request	Enclosed <input type="checkbox"/> To Follow <input type="checkbox"/> Obtain from WIPO <input type="checkbox"/>
IB/306 Recording of Change	Enclosed <input type="checkbox"/> To Follow <input type="checkbox"/> Obtain from WIPO <input type="checkbox"/>
International Application as originally filed (Word format)	Enclosed <input type="checkbox"/> To Follow <input type="checkbox"/>
International Application as published	Enclosed <input type="checkbox"/> To Follow <input type="checkbox"/> Obtain from WIPO <input type="checkbox"/>
English or French translation of International Application	Enclosed <input type="checkbox"/> To Follow <input type="checkbox"/> N/A (Application published in English or French) <input type="checkbox"/>
International Search Report	Enclosed <input type="checkbox"/> To Follow <input type="checkbox"/> Obtain from WIPO <input type="checkbox"/>
Article 19 Amendments (if any)	Enclosed <input type="checkbox"/> To Follow <input type="checkbox"/> Obtain from WIPO <input type="checkbox"/>
International Preliminary Examination Report (Chapter II only)	Enclosed <input type="checkbox"/> To Follow <input type="checkbox"/> N/A <input type="checkbox"/>
Article 34 Amendments (if any)	Enclosed <input type="checkbox"/> To Follow <input type="checkbox"/> N/A <input type="checkbox"/>
Assignment(s) (if any) ³	Enclosed <input type="checkbox"/> To Follow <input type="checkbox"/> N/A <input type="checkbox"/>
Sequence Listing (if any) ⁴	Enclosed <input type="checkbox"/> To Follow <input type="checkbox"/> N/A <input type="checkbox"/>

³The CIPO no longer requires an applicant to record assignments or other title documents to substantiate the applicant’s entitlement to apply for a patent. Even though the CIPO will not require us to do so, we recommend that you provide and instruct us to file copies of any relevant assignments or other title documents which establish the chain of title from the inventor(s) to the applicant. We also recommend that any future changes in ownership of the patent rights (e.g. assignments, mergers, name changes, etc.) be recorded in the CIPO.

⁴An application which discloses nucleotide or amino acid sequences that do not form part of the prior art must contain a sequence listing in computer-readable form containing the actual sequence(s). The computer-readable sequence listing must be filed within three months of national phase entry in Canada, failing which a completion fee will be required.

VIII. Documents Not Required for Canada

We can request National Entry **without** a signed Power of Attorney. A certified copy of the priority document(s) is not ordinarily required.

IX. Special Instructions

Filing deadline: _____

Additional instructions: _____

further additional instructions are attached

X. Mailing Instructions

Please send completed form and attachments to Oyen Wiggs Green & Mutala LLP via

- a) E-mail to mail@patentable.com, or
- b) Fax to 604.681.4081, or
- c) Courier to address below